Nirmatrelvir–Ritonavir Oral para Covid-19 em Pacientes Ambulatoriais de Maior Risco

Butler et al. (Quarta-feira,) estudaram essa questão.

www.synapsesocial.com/papers/69ea386ec2ceeb8fbfae7e96 — DOI: https://doi.org/10.1056/nejmoa2502457

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes· 2024 · 5 citations
2. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial· 2021 · 315 citations
3. The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations· 2021 · 45 citations
4. An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19· 2021 · 1,902 citations
5. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers· 2009 · 1,390 citations